Perfusion
-
Randomized Controlled Trial Comparative Study Clinical Trial
Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction.
The two most commonly used heparin-coated systems for cardiopulmonary bypass (CPB) are the Carmeda Bio-Active Surface (CBAS) (Medtronic, Minneapolis, MN, USA) and the Duraflo II coating (Baxter Healthcare, Irvine, CA, USA). The two surfaces are technically unequal and previous experimental studies have demonstrated disparities in effects on the immune system and blood cells. However, little is known concerning the influence of the two surfaces on markers for brain and myocardial dysfunction. ⋯ Except for a slightly higher elevation of NSE at the end of CPB and 5 h after CPB in the Duraflo II group, there were no significant differences between the CBAS group and the Duraflo II group concerning markers for brain and myocardial dysfunction.
-
Randomized Controlled Trial Clinical Trial
High risk of intraoperative awareness during cardiopulmonary bypass with isoflurane administration via diffusion membrane oxygenators.
In cardiac surgery with the aid of extracorporeal circulation (ECC), inhalation anaesthetics can be administered via the oxygenator. Until the recent advent of a new type of diffusion membrane oxygenator, we routinely added the inhalation agent, isoflurane, to the gas flow of a microporous capillary membrane-type oxygenator. ⋯ This observation led to a prospective randomized study comprising 60 patients and two models of a microporous capillary membrane oxygenator, as well as two models of a diffusion membrane oxygenator. Simultaneous isoflurane concentration measurements at both the gas inlet and outlet ports of the oxygenators showed that, whereas in the microporous capillary-type oxygenators the isoflurane administered was reduced by about 50% during the passage of gas through the device, there was only a minimal transfer of isoflurane in the diffusion-type membrane oxygenators.
-
Randomized Controlled Trial Clinical Trial
Intraoperative treatment strategy to reduce the incidence of postcardiopulmonary bypass atrial fibrillation.
Postcardiopulmonary bypass atrial fibrillation remains a constant complication associated with coronary revascularization, the incidence of which occurs from 20% to 35%. Previous studies have addressed this problem in the postoperative setting utilizing pharmacological agents, but the results have been variable. The purpose of this study was to evaluate a novel intraoperative strategy to reduce the incidence of postcardiopulmonary bypass atrial fibrillation. We theorized that leukocyte depletion by filtration with the addition of aprotinin would reduce the systemic inflammatory effects of bypass and reduce the incidence of atrial fibrillation. ⋯ This novel intraoperative treatment strategy of both mechanical (leukocyte filtration) and pharmacological (aprotinin) intervention appears to markedly reduce the incidence of postcardiopulmonary bypass atrial fibrillation. To our knowledge, this is the first study to combine these two treatment strategies. A previous study has noted a decline in atrial fibrillation with aprotinin in the animal model, but not to the extent observed in our study. The beneficial effects of the reduction of atrial fibrillation include reduced risk of emboli formation and the incidence of ischemia in the heart, lung and brain. In addition, a decrease in length of hospital stay, recovery time and overall cost occurred.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Should we rely on nasopharyngeal temperature during cardiopulmonary bypass?
A potential morbidity of incomplete re-warming following hypothermic cardiopulmonary bypass (CPB) is cardiac arrest. In contrast, attempts to fully re-warm the patient can lead to cerebral hyperthermia. Similarly, rigid adherence to 37.0 degrees C during normothermic CPB may also cause cerebral overheating. ⋯ During the re-warming phases of CPB, we were unable to make any correlation between NP temperature and arterial blood temperature, using body weight or body mass index as predictors. Based on the results obtained, we recommend that strict criteria should be implemented for the management of temperature during CPB, in conjunction with more emphasis being placed on monitoring arterial blood temperature as a marker of potential cerebral hyperthermia. We should, therefore, not rely on NP temperature measurement alone during CPB.
-
Randomized Controlled Trial Clinical Trial
The relationship between mixed venous and regional venous oxygen saturation during cardiopulmonary bypass.
The relationship between mixed venous and regional venous saturation during cardiopulmonary bypass (CPB), and whether this relationship is influenced by temperature, has been incompletely elucidated. Thirty patients undergoing valve and/or coronary surgery were included in a prospective, controlled and randomized study. The patients were allocated to two groups: a hypothermic group (28 degrees C) and a tepid group (34 degrees C). ⋯ In conclusion, regional deoxygenation occurs during CPB, in spite of normal mixed venous saturation. Mixed venous oxygen saturation correlates with hepatic, but not with jugular, vein saturation. The level of hypothermia does not influence differences in oxygen saturation between mixed venous and regional venous blood.